Operated under the auspices of the Duke Clinical Research Institute, this laboratory is the oldest and largest academic eECG Core Laboratory in the world.

The laboratory is active in the development of:

• New electronic ECG waveform monitoring devices
• State-of-the-art technology applications to capture cardiac safety and efficacy measures in multicenter global clinical trials

In ST segment elevation myocardial infarction (STEMI) and acute coronary syndromes, quantitative ST-segment analyses performed in more than 10 million ECGs have measured therapeutic benefit of drugs and devices in many trials, making ST-segment monitoring the most well established biomarker of cardiac efficacy.

Trials in which ST-segment monitoring has measured therapeutic benefit:

• TAMI 5, TAMI 7, TAMI 9
• DUCCS II,
• HERO
• GUSTO I
• IMPACT-AMI
• PRIME
• PARADIGM
• GUSTO-V
• INTEGRITI CASTEMI
• EMERALD
• AMIHOT
• LOWTEMP
• FLAME
• CRAFT

In cardiac safety, eECG QT and QTc measures with all new molecular entities, including non-cardiac drugs. are now mandated by the FDA and provide an exciting new area of cardiac expertise and eECG technologies. 

Additional developing research areas include:

• Applications of multiple biomarkers (ST recovery, reperfusion arrhythmias, sestamibi perfusion infarct size, CPK enzyme curves) to advance predictive information and new therapy assessment in STEMI intervention
• Use of derived ECG from reduced lead sets for ischemia monitoring
• Emergency Department risk stratification of patients with chest pain and nondiagnostic ECG's
• Pre-hospital and chest pain evaluation using novel ECG systems
• Optimal assessment of cardiac risk with QT/QTc
• Reperfusion arrhythmias and fibrillation